An Introduction to Paediatric Neurology
Paediatric neurology, relating to children from birth to young adulthood, is a challenging area of medicine requiring collaboration between the paediatrician, adult neurologist and specialist paediatric neurologist. Advancing treatments in disorders such as epilepsy, brain and spinal tumours, neuromuscular disorders, and inborn errors of metabolism, show promise for the future of these patients.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Paediatric Neurology Content
Addressing unmet needs to improve outcomes for people with epilepsy
Keep up to date on the latest developments by watching this webinar discussing key issues in the treatment and management of severe epilepsy, focussing on: The key unmet medical needs that still exist for people with severe epilepsy. How the latest clinical trial results support emerging therapeutic options to address these unmet needs. Challenges and insights that the COVID-19 pandemic has revealed about the diagnosis, treatment and management of people with epilepsy. Part 1: Watch the webinar with three internationally renowned experts discussing key issues in the treatment and management of severe epilepsy Watch Now Part 2: Watch the interview…
- Assess the main diagnostic approaches in epilepsy and the challenges that remain in the management and monitoring of the disease, particularly during the COVID-19 pandemic
- Recognize the key medical unmet needs that remain for people with epilepsy, especially with conditions that are often refractory to conventional anti-epileptic drugs, such as encephalopathic epilepsies
- Describe recent therapeutic developments in epilepsy, evaluate the supporting clinical evidence, and appreciate how they might impact quality of life beyond symptom control
Key developments in the diagnosis, treatment and understanding of childhood-onset, treatment-resistant epilepsies with Dr Antonietta Coppola & Dr Angel Aledo-Serrano
Watch this two-part activity discussing diagnostic and therapeutic advances in the field of childhood-onset treatment-resistant epilepsy from AES 2020 Part 1: Watch internationally renowned expert Dr Antonietta Coppola review key data from the conference focussing on genetic diagnosis and treatments Watch Now Part 2: Choose from two leading experts who discuss how data presented at the AES 2020 may affect daily practice Select An Interview
- Recognise the unmet needs and challenges that remain for people living with childhood-onset, treatment-resistant epilepsies.
- Understand the challenges that remain in the management and monitoring of the childhood-onset epilepsies, and be aware of the key diagnostic advances presented at AES 2020.
- Describe the key therapeutic developments for childhood-onset, treatment-resistant epilepsies presented at AES 2020.
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
Kelly Knupp, AES 2020 – Fenfluramine for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, […]
Cannabidiol Oral Solution – A New Class of Antiseizure Medication
European Neurological Review. 2020;15(1):19–26 DOI: https://doi.org/10.17925/ENR.2020.15.1.19
Epilepsy is one of the most common neurological disorders, affecting around 70 million people worldwide.1,2 Its management is mainly symptomatic, and long-term seizure remission is achieved in most cases.3,4 One-third of patients, however, continue to experience seizures despite adequate treatment.5 Remarkably, the burden of refractory epilepsy has remained stable over the last decades despite increasing therapeutic resources, including […]
Epilepsy FOCUS: Shared experience of cannabidiol
In the following two webinars, seven leading experts discuss case studies of patients treated with GW CBD, reviewing patient profiles, optimal dosing and titration, management of adverse events and polytherapy, and initiating GW CBD in patients previously on non-regulatory approved cannabis-based products. The topics highlighted in the webinars can easily be accessed from the panel on the left side of the page. This content is available for free to registered users, and is intended for HCPs only.
- Describe some of the diverse profiles of patients who may benefit from cannabidiol
- Understand how to initiate GW CBD and reach optimal dosing
- Discuss potential strategies to manage patients experiencing adverse events (AEs)
- Understand how to manage patients with previous or current experience of non-regulatory approved cannabis-based products
DSUK – Dravet Syndrome in the COVID-19 Pandemic – Webinar with Professor Helen Cross OBE
Video produced by and shared with kind authorisation of Dravet Syndrome UK (DSUK). Professor Helen Cross OBE is a globally-recognised authority on Dravet Syndrome and Chair of DSUK’s Medical Advisory Board. On Monday 30 March, she took part in a webinar for families registered with DSUK, presenting on COVID-19 and answering a range of questions. […]
Christopher Glisson, AAN 2019 – Updates in pediatric neuro-ophthalmology
Christopher Glisson (Mercy Health Hauenstein Neurosciences, Michigan, USA) kindly took the time to talk us on the topic of his update session at AAN on pediatric neuro-ophthalmology. Questions What are the particular challenges of paediatric as opposed to adult neuro-ophthalmology? (0:04) What are the most commonly seen optic neuropathies in childhood? (0:47) What is […]
The Untold Story of the Cannabidiol (CBD) Revolution
US Neurology. 2018;14(Suppl. 3):2–8
In 1998, a British physician named Dr Geoffrey Guy heard the knock of opportunity. Always a visionary, he gathered his unique set of skills and experience, and responded. The events that followed contributed significantly to cannabidiol’s (CBD’s) emergence from relative obscurity into broad public consciousness (personal interview with Guy G, October 31, 2017).1 Dr Guy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!